BIO Comments on FDA Draft Guidance on Pediatric Rare Diseases – A Collaborative Approach for Drug Development Using Gaucher Disease as a Model
February 5, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Pediatric Rare Diseases – A Collaborative Approach for Drug Development Using Gaucher Disease as a Model.
BIO appreciates the FDA’s intended goal with the guidance – to reduce the total number of children needed for enrollment in clinical studies – and applauds the agency’s willingness to accept innovative trial designs to limit the number of patients in the control arm and thereby improve trial efficiency.
However, BIO has concerns with the guidance, particularly with the FDA’s suggestion for the use of multi-arm, multi-company clinical studies, which have inherent limitations and challenges. In the comments, BIO details these concerns and provides suggestions for clarifying and improving the guidance.
Download Full Comments Below
BIO Letter Pediatric Rare Diseases A Collaborative Approach For Drug Development Using Gaucher Disease As A Model FDA-2017-N-6476
On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Pediatric Rare Diseases – A Collaborative Approach for Drug Development Using Gaucher Disease as a Model.
BIO appreciates the FDA’s intended goal with the guidance – to reduce the total number of children needed for enrollment in clinical studies – and applauds the agency’s willingness to accept innovative trial designs to limit the number of patients in the control arm and thereby improve trial efficiency.
However, BIO has concerns with the guidance, particularly with the FDA’s suggestion for the use of multi-arm, multi-company clinical studies, which have inherent limitations and challenges. In the comments, BIO details these concerns and provides suggestions for clarifying and improving the guidance.